CM 24

Drug Profile

CM 24

Alternative Names: CM24; MK 6018

Latest Information Update: 19 Aug 2016

Price : $50

At a glance

  • Originator cCAM Biotherapeutics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD66 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 03 Jun 2016 Pharmacodynamics data from preclinical studies in Solid tumours presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2016)
  • 01 Feb 2015 Phase-I clinical trials in Solid tumours (Late-stage disease, Recurrent) in Israel (IV)
  • 01 Feb 2015 Phase-I clinical trials in Solid tumours (Late-stage disease, Recurrent) in USA (IV) after February 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top